Your browser doesn't support javascript.
loading
An Exploratory Study Using Electronic Medical Records to Assess the Feasibility of Establishing Cohorts of Patients with Genetic Causes of Parkinson's Disease.
Lee, Susan J; Shaw, Peter M; Thornton, Bob; Kumar, Amit; Eizik, Michal; Goldstaub, Dan; Braun, Tali; Teper, Gally; Pai, Jennifer K; Chodick, Gabriel; Bienfait, Karina; Levitan, Diane; Beller, Daniella; Chris Min, K; Jonathan, Daniel; Voss, Tiffini; Fox, Caroline S; Aubrey Stoch, S; Struyk, Arie F; Vainstein, Gabriel.
Afiliação
  • Lee SJ; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Shaw PM; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Thornton B; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Kumar A; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Eizik M; MSD Israel, Hod Hasharon, Israel.
  • Goldstaub D; MSD Israel, Hod Hasharon, Israel.
  • Braun T; MSD Israel, Hod Hasharon, Israel.
  • Teper G; MSD Israel, Hod Hasharon, Israel.
  • Pai JK; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Chodick G; Maccabi Healthcare Services, Tel Aviv, Israel.
  • Bienfait K; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Levitan D; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Beller D; Maccabi Healthcare Services, Tel Aviv, Israel.
  • Chris Min K; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Jonathan D; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Voss T; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Fox CS; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Aubrey Stoch S; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Struyk AF; Merck & Co., Inc., Kenilworth, NJ, USA.
  • Vainstein G; Maccabi Healthcare Services, Tel Aviv, Israel.
J Parkinsons Dis ; 12(5): 1645-1653, 2022.
Article em En | MEDLINE | ID: mdl-35466950
BACKGROUND: More efficient screening methods are needed to improve the ability to identify and follow genetic cohorts in Parkinson's disease (PD). OBJECTIVE: To explore the use of the electronic medical records (EMRs) to identify participants with PD. METHODS: Using an algorithm previously developed in collaboration with Maccabi Healthcare Services (MHS), approximately 5,200 participants with PD were identified, more than 3,200 were screened, and 837 participants were enrolled and genotyped for leucine-rich repeat kinase 2 (LRRK2) and beta-glucocerebrosidase (GBA) variants. Questionnaires were completed to ascertain Ashkenazi Jewish (AJ) ancestry and family history of PD. RESULTS: Among 837 participants with PD, 82% were 65 years and older and 72% had a family history of AJ ancestry. Among those with AJ ancestry, 15.6% reported having relatives with PD. The frequency of observed mutations for LRRK2 and GBA genes combined was approximately 15.4%. The frequency of observed LRRK2 mutation was 6.1% overall and 7.2% from those with AJ ancestry; and for GBA mutation was 9.3% overall and 11.2% from those with AJ ancestry. CONCLUSION: Although the frequency of observed mutations in this study was lower than anticipated, mutation carriers were enriched among those with a family history of AJ ancestry increasing nearly 2-3-fold, from 3% -7% (LRRK2) and 4% -11% (GBA). The identification (and selection) of PD patients through EMRs prior to genotyping is a viable approach, to establish a genetically defined cohort of patients with PD for clinical research.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doença de Parkinson Idioma: En Ano de publicação: 2022 Tipo de documento: Article